Adcetris (brentuximab vedotin)
Adcetris (Brentuximab Vedotin) is a targeted antibody-drug conjugate (ADC) used to treat certain types of lymphoma, including classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It combines a CD30-targeting monoclonal antibody with a potent anticancer agent to selectively identify and destroy cancer cells while minimizing damage to healthy tissues.
Brukinsa (zanubrutinib)
Brukinsa (Zanubrutinib) is an oral targeted therapy used to treat certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other blood cancers. As a Bruton's tyrosine kinase (BTK) inhibitor, it works by blocking signals that promote the growth and survival of malignant B cells, helping to control disease progression and improve patient outcomes.
Calquence (acalabrutinib)
Calquence (Acalabrutinib) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As a Bruton's tyrosine kinase (BTK) inhibitor, it works by blocking signals that promote the growth and survival of malignant B cells, helping to slow disease progression and improve patient outcomes.
Darzalex (Daratumumab)
Enhertu (Trastuzumab Deruxtecan)
Enhertu (Trastuzumab Deruxtecan) is an advanced antibody-drug conjugate (ADC) used to treat certain HER2-positive and HER2-low cancers, including breast, gastric, and lung cancers. It combines targeted antibody therapy with a potent anticancer agent to selectively attack cancer cells while minimizing damage to healthy tissues.
Erleada (apalutamide)
Erleada (Apalutamide) is an oral targeted therapy used for the treatment of specific forms of prostate cancer. It works by inhibiting androgen receptors, blocking the effects of male hormones that promote the growth and spread of prostate cancer cells, thereby helping to slow disease progression and improve clinical outcomes.
Ibrance (palbociclib)
Ibrance (Palbociclib) is an oral targeted therapy used for the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), helping to slow the growth and spread of cancer cells while improving treatment outcomes when used in combination with endocrine therapy.
Imbruvica (Ibrutinib)
Imbruvica (Ibrutinib) is an oral targeted therapy used to treat several blood cancers and chronic immune disorders. It works by inhibiting Bruton's tyrosine kinase (BTK), a protein that plays a key role in the growth and survival of certain cancerous B cells, helping to slow disease progression and improve patient outcomes.
Imfinzi (durvalumab)
Imfinzi (Durvalumab) is an advanced immunotherapy medicine used to treat several types of cancer, including lung cancer and biliary tract cancer. As a PD-L1 inhibitor, it helps the body's immune system recognize and attack cancer cells more effectively, providing a targeted approach to cancer treatment.
Jakafi (ruxolitinib)
Jakafi (Ruxolitinib) is an oral targeted therapy used to treat certain blood disorders and immune-related conditions, including myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). It works by inhibiting Janus kinase (JAK) pathways that contribute to abnormal blood cell production and inflammatory responses.
Kadcyla (trastuzumab emtansine)
Kadcyla (Trastuzumab Emtansine), also known as T-DM1, is a targeted antibody-drug conjugate (ADC) used to treat HER2-positive breast cancer. It combines the HER2-targeting properties of trastuzumab with a potent anticancer agent, allowing for precise delivery of chemotherapy directly to cancer cells while minimizing effects on healthy tissues.
Keytruda (Pembrolizumab)
Keytruda (Pembrolizumab) is a prescription immunotherapy medicine used to treat various types of cancer by helping the body's immune system recognize and fight cancer cells more effectively. It belongs to a class of medicines known as PD-1 inhibitors and is widely used in the treatment of melanoma, lung cancer, head and neck cancer, kidney cancer, bladder cancer, and several other malignancies.
